University of Cambridge
Case Studies

STORM Therapeutics: Paving the way for new treatments by modifying RNA

19 November 2024
Insight

Jason Mellad, CEO of spin-out Cambridge Epigenetix, discusses commercialising University research

29 November 2017
News

Storm Therapeutics secures £12m investment

28 June 2016
News

Cambridge Epigenetix raises $5.5M

31 October 2014
Case Studies

Sequencing: How large is the alphabet of DNA?

12 December 2013
News

New technique transforms epigenetics research

26 April 2012
News

CellCentric Licenses Novel Epigenetic Discovery Programme to Takeda

04 March 2010